SCHEMBL5744191

SCHEMBL5744191

C=C(C)C[C@H](NC(=O)c1ccc(NC(=N)N)cc1)C(=O)N[C@@H]1C(=O)CO[C@@H]1C

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CTSL P07711 20/20 0.42
CTSS P25774 19/20 0.42
CTSK P43235 19/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475887 0.89 CTSL (0.45) CTSLCTSSCTSK
SCHEMBL5744598 0.88 CTSK (0.46) CTSLCTSSCTSK
SCHEMBL6488393 0.88 CTSL (0.49) CTSLCTSSCTSK
SCHEMBL5743408 0.87 CTSK (0.49) CTSLCTSSCTSK
SCHEMBL6481128 0.85 CTSL (0.44) CTSLCTSSCTSK
SCHEMBL6514275 0.85 CTSL (0.45) CTSLCTSSCTSK
SCHEMBL5743441 0.85 CTSK (0.50) CTSLCTSSCTSK
SCHEMBL6486342 0.84 CTSL (0.46) CTSLCTSSCTSK
SCHEMBL6481730 0.84 CTSL (0.47) CTSLCTSSCTSK
SCHEMBL5742589 0.79 CTSK (0.51) CTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358183-B1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2006-04-12 EP disclosed
US-20050070598-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2005-03-31 US disclosed
US-20040229915-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070598-A1 Cysteine protease inhibitors CTRL, CTSZ, CTSS CTSL 13/4885CTSS 3/4885CTSK 5/4885
US-20040229915-A1 Cysteine protease inhibitors C1R, CTRL, CTSK CTSL 9/4885CTSS 4/4885CTSK 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.